ArticleEuropean thyroid journal2021
Prevalence and Treatment Outcomes of Marine-Lenhart Syndrome in Japan.
Article in European thyroid journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- Development of Graves' Disease after Resection of an Autonomously Functioning Thyroid Nodule.Internal medicine (Tokyo, Japan) · 2025Article
- Hyperthyroidism From Graves Disease Relapsed as Hot Nodule.JCEM case reports · 2025Article
- Synchronous Presentation of Type 2 Marine-Lenhart Syndrome and Differentiated Thyroid Carcinoma Manifesting as Thyroid Storm.Case reports in endocrinology · 2025Article
- Unilateral Graves' Orbitopathy in a Patient with Marine-Lenhart Syndrome: A case report.Sultan Qaboos University medical journal · 2024Article
- A Rare Case of Papillary Thyroid Carcinoma in Marine-Lehnhart Syndrome-Indication for Biopsy of Hot Thyroid Nodules?JCEM case reports · 2024Article
- A case of Marine Lenhart syndrome with Hashimoto's thyroiditis that mimicked thyroid carcinoma.BMC endocrine disorders · 2023Article
- The prevalence and significance of nonuniform thyroid radio-isotope uptake in patients with Graves' disease.Clinical endocrinology · 2022Article
- Marine-Lenhart Syndrome: A Rare Presentation of Thyroid Disease.AACE clinical case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMarine-Lenhart syndrome (MLS) is now understood to be a combination of Graves' disease and autonomously functioning thyroid nodule(s) (AFTNs). The prevalence of the syndrome and suitable treatments for those living in iodine-sufficient areas are uncertain.
objectivesWe aimed to investigate the prevalence, treatment, and prognosis of MLS in Japan, an iodine-sufficient area.
methodsThis study involved patients who visited our hospital between February 2005 and August 2019. Among patients with both thyrotoxicosis and thyroid nodule(s) larger than 10 mm, MLS and isolated AFTNs were diagnosed based on serum thyroid-stimulating hormone receptor antibody levels and scintigraphy using radioiodine or technetium-99m and thyroid uptake.
resultsTwenty-two patients were found to have MLS, compared to 372 with isolated AFTNs and 8,343 with Graves' disease, during the period. Therefore, the rate of MLS cases was 0.26% among all patients with Graves' disease (22/8,343). Treatments and outcomes were assessed for cases of MLS (
conclusionsThe prevalence of MLS among patients with Graves' disease was 0.26% in Japan. RAI therapy induces hypothyroidism more frequently than in those with AFTNs probably because RAI is taken up in the surrounding Graves' tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.